bluuebunny/crossref_metadata_2025_split huggingface dataset:
Following carpel tunnel release, what factors affect whether patients return to the same or different hand surgeon for a subsequent procedure?
Authors: Halperin Scott J. , Dhodapkar Meera M. , Pathak Neil , Joo Peter Y. , Luo Xuan , Grauer Jonathan N. 
Published: October 2024

Background
Following carpal tunnel release (CTR), patients may be indicated for subsequent hand surgery (contralateral CTR and/or trigger finger release [TFR]). While surgeons typically take pride in patient loyalty, the rate of returning to the same hand surgeons has not been previously characterized.

Methods
Patients undergoing CTR were isolated from 2010–2021 PearlDiver M151 dataset. Subsequent CTR or TFR were identified and characterized as being performed by the same or different surgeon, with patient factors associated with changing to a different surgeon determined by multivariable analyses.

Results
In total, 1,121,922 CTR patients were identified. Of these, subsequent surgery was identified for 307,385 (27.4%: CTR 289,455 [94.2%] and TFR 17,930 [5.8%]). Of the patients with a subsequent surgery, 257,027 (83.6%) returned to the same surgeon and 50,358 (16.4%) changed surgeons. Multivariable analysis found factors associated with changing surgeon (in order of decreasing odds ration [OR]) to be: TFR as the second procedure (OR 2.98), time between surgeries greater than 2-years (OR 2.30), Elixhauser-Comorbidity Index (OR 1.14 per 2-point increase), and male sex (OR 1.06), with less likely hood of changing for those with Medicare (OR 0.95 relative to commercial insurance) (p<0.001 for each). Pertinent negatives included: age, Medicaid, and having a 90-day adverse event after the index procedure.

Conclusions
Over fifteen percent of patients who required a subsequent CTR or TFR following CTR did not return to the same surgeon. Understanding what factors lead to outmigration of patients form a practice may help direct efforts for patient retention.
Dietary patterns during pregnancy in relation to maternal dietary intake: The Mutaba’ah Study
Authors: Almulla Aisha A. , Augustin Hanna , Ahmed Luai A. , Bärebring Linnea 
Published: October 2024

Aim
To relate adherence to healthy dietary patterns, evaluated by different dietary indices, to the intake of nutrients and food groups among pregnant women in the United Arab Emirates.

Methods
The analyses included 1122 pregnant women from the Mutaba’ah Study. Dietary intake was assessed using a semi-quantitative Food Frequency Questionnaire. Adherence to three dietary pattern indices was assessed; Alternate Healthy Eating Index for Pregnancy (AHEI-P), Alternate Mediterranean Diet (aMED) and Dietary Approaches to Stop Hypertension (DASH). Associations between adherence (score >median) to the three dietary indices and intake of nutrients and food groups were analyzed using logistic regression analysis.

Results
Women with higher intake of polyunsaturated fatty acids, fiber, vegetables, fruits, legumes, and nuts and lower intake of saturated fatty acids, red meat, and sweetened beverages had significantly higher odds of adherence to all three dietary patterns (p<0.05). Associations between intakes of nutrients and food groups with odds of adherence to the dietary patterns differed for total fat (only with AHEI-P, [odds ratio [OR]: 0.96; 95% confidence interval [CI]: 0.94–0.98]) and monounsaturated fatty acids (only with aMED, [OR: 1.06; 95% CI: 1.02–1.10]), dairy (with AHEI-P [OR: 0.89; 95% CI: 0.84–0.95] and aMED [OR: 0.86; 95% CI: 0.81–0.91], and with DASH [OR: 1.10; 95% CI: 1.04–1.17]), whole grain (only with aMED [OR: 2.19; 95% CI: 1.61–2.99] and DASH [OR: 4.27; 95% CI: 3.04–5.99]) and fish (with AHEI-P [OR: 1.36; 95% CI: 1.02–1.80] and aMED [OR: 1.79; 95% CI: 1.35–2.38], and with DASH [OR: 0.67; 95% CI: 0.52–0.86]).

Conclusion
Adherence to the three dietary pattern indices was generally associated with a favorable intake of nutrients and food groups. However, the indices captured slightly different aspects of dietary intake. These results show that dietary indices that assess adherence to healthy dietary patterns cannot be used interchangeably.
Adverse events analysis of Relugolix (Orgovyx®) for prostate cancer based on the FDA Adverse Event Reporting System (FAERS)
Authors: Li Ruibo , Chen Xi , Wang Yujie 
Published: October 2024

Background
Due to the limitations of clinical trials, some delayed and rare adverse events (AEs) may remain undetected, and safety information can be supplemented through post-market data analysis. This study aims to comprehensively analyze the AEs associated with Relugolix (Orgovyx®) using data from the FAERS database, and gain a better understanding of the potential risks and side effects of Relugolix (Orgovyx®) therapy.

Methods
Data of Relugolix (Orgovyx®) were collected from the FAERS database covering the period from the fourth quarter of 2020 to the third quarter of 2023. Disproportionality analysis was performed by calculating the reporting odds ratios (ROR), proportional reporting ratio (PRR), Bayesian analysis confidence propagation neural network (BCPNN), and the multi-item gamma Poisson shrinker (MGPS) to detect positive signals.

Results
Totally, 5,382,189 reports were collected from the FAERS database, 4,397 reports of Relugolix (Orgovyx®) were identified as the ‘primary suspected (PS)’ AEs. Relugolix (Orgovyx®) induced AEs occurred in 26 organ systems. 58 significant disproportionality preferred terms (PTs) satisfying with the four algorithms were retained at the same time. Unexpected significant AEs such as Pollakiuria, and Prostatic specific antigen increased also occur. The median time of onset was 60 days. The majority of the AEs occurred within the first 30 days after Relugolix (Orgovyx®) initiation.

Conclusion
Common AEs included Hot flush, Fatigue, Asthenia, Constipation, and Myalgia. These AEs should be focused on when using the drug to avoid serious consequences. In addition, the study results also suggested that the drug may exist Pollakiuria, Prostatic specific antigen increased and other AEs not mentioned in the manual, to supplement the AEs in the manual. This study is helpful for clinicians and pharmacists to improve their understanding of Relugolix (Orgovyx®) related AEs, and take timely prevention and treatment measures to ensure drug safety for patients.
Clinical and instrumental characteristics of osteoarthritis in hyperuricemia
Authors: Taskina E. A. , Lila A. M. , Alekseeva L. I. , Kashevarova N. G. , Mikhailov K. M. , Halmetova A. R. , Strebkova E. A. , Sharapova E. P. , Savushkina N. M. , Kudinskiy D. M. , Raskina T. A. , Vinogradova I. B. 
Published: October 2024

Objective: to investigate in a multicentre single-stage study the relationships between hyperuricemia (HU) and clinical, instrumental and laboratory parameters of osteoarthritis (OA).Material and methods. The study included 200 patients aged 40 to 75 years with a definite diagnosis of knee (KN) OA that met ACR criteria, with stage I–III OA by Kellgren–Lawrence. The mean age of the patients was 55.9±10.3 years and the body mass index (BMI) was 29.4±6.2 kg/m2. An individual chart was completed for each patient, including anthropometric parameters, medical history and clinical examination data, visual analogue scale (VAS) assessment of KN pain, WOMAC, patient's general health assessment (GHA) and information on comorbidities. All patients underwent standard radiography and magnetic resonance imaging (MRI) of the KN (WORMS), dual-energy X-ray absorptiometry of the lumbar spine and femoral neck, and laboratory examination.Results and discussion. HU was diagnosed in 57 (28.5) patients when the serum uric acid (UA) level was above 360 μmol/L. Patients were divided into two groups according to the presence or absence of HU. The age of the patients in the two groups was comparable, but they differed significantly in terms of disease duration, BMI, waist and hip circumference, which were greater in the HU group (p <0.05). Statistically significant differences were also found in the assessment of the severity of OA course: there were higher pain indices according to VAS, WOMAC total score and its components (pain and functional impairment, FI), GHA in the HU group. On MRI, osteitis was more common in the medial aspect of the tibia (odds ratio 5.75; 95% confidence interval 1.29–25.6; p=0.03). Patients with HU had higher concentrations of CRP, COMP, leptin, insulin, triglycerides and creatinine (p <0.05 for all values).Spearman correlation analysis confirmed the association between HU and duration and radiological stage of OA, the presence of osteitis in the medial aspect of tibia detected by MRI, pain according to VAS and WOMAC, FI according to WOMAC and GHA (p<0.05).Conclusion. At high UA levels, pain values according to VAS and WOMAC are higher, GHA is worse, and CRP and COMP levels are elevated. MRI shows more frequent osteitis in the medial aspect of the tibia in patients with HU. Deciphering the mechanisms that determine the relationship between HU and OA is important for the development of new methods for the prevention and treatment of these diseases.
Investigation of the analgesic efficacy of local therapy with non-steroidal anti-inflammatory drugs in patients with knee osteoarthritis
Authors: Strebkova E. A. , Taskina E. A. , Kashevarova N. G. , Sharapova E. P. , Savushkina N. M. , Korotkova T. A. , Alekseeva L. I. , Lila A. M. 
Published: October 2024

Objective: to analyze the extent of analgesic effect and to determine predictors of inadequate response to local therapy with non-steroidal antiinflammatory drugs (NSAIDs) in a prospective, comparative, randomized trial of the efficacy and safety of Artoxan® gel 1% versus Diclofenac gel 1% in patients with knee OA.Material and methods. The study included 60 patients with a definite diagnosis of stage II–III Kеllgren–Lawrence knee OA who fulfilled ACR criteria and were observed on an outpatient basis in V.A. Nasonova Research Institute of Rheumatology. Patients were 40–80 years old (mean 62.50±8.04 years), body mass index (BMI) 24.9±4.67 kg/m2 , median OA duration 5.7 [3;15] years. According to the randomization scheme, the patients were divided into two groups. In the 1st group (n=30), local therapy with 1% Artoxan gel was applied to the target area of the knee twice daily for 14 days. Patients in the 2nd group (n=30) were prescribed local therapy with the comparator drug, 1% Diclofenac gel with a similar application regimen. Patients in both groups were comparable in terms of the main parameters.Results and discussion. Patients in both groups showed a significant decrease in pain intensity in the target joint during walking according to the visual analogue scale (VAS) after two weeks of treatment (p <0.05). A decrease in pain (to mild or moderate) in the target joint to <40 mm according to VAS after 7 days of therapy reported 43.3% of patients in the 1st group, and 63.3% of patients after 14 days of therapy (p=0.09). In the 2nd group, 43.3 % of patients also reported a reduction in pain in the target joint to <40 mm according to VAS after 7 days of therapy, and after 14 days it was observed in 56.7% of cases (p=0.22). Although the differences between the groups did not reach statistical significance, a reduction in pain to <40 mm according to VAS and a high BMI (r= -0.28; p=0.029).Conclusion. The results of the study demonstrate a significant analgesic effect of local NSAIDs in knee OA. In most patients, pain was <40 mm according to VAS after 2 weeks of local NSAID therapy. At the same time, there was a tendency towards a higher frequency of pain reduction to <40 mm according to VAS in the group receiving local therapy with 1% Artoxan gel. It was concluded that excessive body weight and high BMI may be predictors of inadequate analgesic effect in patients with knee OA.
The Effect of Adding Agomelatine to Escitalopram in the Treatment of Major Depressive Disorder
Authors: Azadi H. , Rashidpour P. , Yassini Ardekani S. M. , Nadi Sakhvidi M. , Afshang H. , Bidaki R. 
Published: October 2024

Major Depressive Disorder (MDD) is a psychiatric illness that imposes a high cost on the patient and the community. Over the past few decades, a variety of treatments have been used to treat depression. One of the most common treatments for depression is medication. Today, specific serotonin reuptake inhibitors are the first line of treatment for major depression. Another drug that has been considered in the treatment of depression is agomelatine.Objective of this study was to evaluate the effect of adding agomelatine to Escitalopram in treatment of major depressive disorder.Materials and methods. This study was a double-blind randomized clinical trial with before and after designs (b and a). In this study, 70 patients with MDD referred to psychiatric clinics affiliated with Yazd University of Medical Sciences were studied. Patients were randomly divided into two groups of 35 patients (agomelatine + Escitalopram and Escitalopram + placebo) and were treated for 12 weeks. Depression Scale was the Hamilton Depression Inventory and was assessed before treatment, 1, 2, and 3 months after treatment. Variables such as gender, age, marital status, level of education, occupation, and duration of illness were also collected. The data were entered into SPSS version 18 software and analyzed using statistical tests.Results. Of the 70 patients studied, 31 (44.3%) were male and 39 (55.7%) were female. There was not significant difference between gender distribution (p=0.810), marital status(p=0.789), job (p=0.651) and educational level (p=0.794). Also, no significant difference was found between the mean variables: age (p=0.563) and duration of depression (p=0.958). There was a statistically significant difference between the mean score of depression 2 months after treatment (p=0.10) and 3 months after treatment (p=0.023) in the two groups. Also the mean depression score after treatment compared to before, was significantly lower in both groups (p=0.000). Also, no significant difference was found between the frequency of drug side effects in the two groups (p=0.970).Conclusion. Adding agomelatine to Escitalopram is more effective than mood-boosting depression as a result of depression or depressive disorder alone.Future researchers in the field of MDD treatment could consider investigating the long-term effects and comparative efficacy of combining agomelatine with other antidepressants beyond Escitalopram to further enhance treatment outcomes for patients with MDD.
The neuropharmacological and clinical effects of lutein: a systematic review
Authors: Firozjae Atefeh Arab , Shiran Mohammad Reza , Rashidi Mohsen 
Published: October 2024

Abstract

Objectives
Neurodegenerative diseases are defined by specific protein accumulation and anatomic vulnerability leading to neuronal loss. Some studies have shown that lutein may have an effect on neurodegenerative diseases. As most of the neurodegenerative diseases don’t have certain cure and therapies focus on symptom control, Lutein may be a complementary treatment. Due to controversies in studies investigating lutein effect on neurodegenerative diseases, we decided to perform a systematic review on these studies.

Methods
A systematic search was carried out in the available databases. We used all MeSH terms and relevant keywords. Studies that reported relationship between lutein and any neurodegenerative disease were included.

Results
We found 278 studies. After removing duplicates, screening by titles and abstracts and excluding irrelevant papers, 17 articles were included in this study. Fourteen studies investigated Alzheimer’s disease, 2 studies Parkinson’s disease and 1 study Amyotrophic lateral sclerosis. 1/17 study found that high serum levels of lutein at baseline were associated with a lower risk of AD mortality and lutein effect on lipid profile have been investigated in 2/17 studies. Also, 1/17 study has been shown that high intake of lutein may reduce the risk of ALS progression.

Conclusions
4/17 studies confirm that lutein can improve cognitive function. 8/17 studies demonstrate a reduction in the progression of AD, and 2/17 studies indicate an improvement in lipid profiles. However, some studies did not find any significant associations. Additionally, there is a limited number of studies investigating the effects of lutein on other neurodegenerative diseases.
The Apocalypse of Peter as the Origin of the Christian Hell. Sense and Purpose of the Afterlife Punishment in Fire
Authors: Kiel Nikolai 
Published: October 2024

Abstract
Since the announcement of the punishment in the Apocalypse of John, the sentence of the godless in the lake of fire has occupied a central role in early Christian apocalypses. The punishment for the wicked in the lake of fire has acted as a deterrent and paints a terrible portrait that awaits the evil and the unbelievers. During the development of the eschatological motif, apostates and unfaithful Christians have also been included in the fiery punishments. What is the function and purpose of the early Christian apocalypses? This question will be examined in the second-century Apocalypse of Peter. As a result, this paper argues that the Apocalypse of Peter is a work intended to convey comfort to the believers in Christ who were threatened and suffered persecution.
Full-space trifunctional metasurface with independent control of amplitude and phase for circularly polarized waves
Authors: Li Xi Ming , Zhao Yuan , Lu Ren Pan , Sun Xiao Feng , Yang Zhao , He Hai Dan , Liu Yan Hui , Du Guo Hong 
Published: October 2024

Abstract
Flexible and diverse manipulation of electromagnetic (EM) waves in half space (reflection or transmission) has facilitated strong aspiration toward full-space wave control. However, it remains challenging to achieve independent amplitude and phase control, which seriously hinder the real-world applications. Herein, an innovative strategy of trifunctional metasurface is proposed to independently and simultaneously manipulate the amplitude and phase of circular polarized waves in full space. The multifunctional design is composed of double-layer anisotropic metasurface sandwiched with a bandpass frequency selective surface, with a frequency-direction multiplexed paradigm for on-demand control of both amplitude and phase across three independent channels. To validate the concept, a multifunctional metadevice is designed and verified by simulations and experiments, showcasing arbitrary near-field and far-field power modulation in full space. Lateral and axial bifocal metalenses with desired intensity distribution are designed in two reflection channels at 9 GHz, while multibeam generator with desired spatial scatterings and power allocations is designed in transmissive channel at 13 GHz. The finding paves the way for attaining multifunctional metadevices with amplitude and phase modulation in full space, which have potential applications in high-quality imaging and high-capacity communication systems.
Beyond conventional therapy: Synthesis of multifunctional nanoparticles for rheumatoid arthritis therapy
Authors: Ma Xinran 
Published: October 2024

Abstract
Rheumatoid arthritis (RA) is a persistent inflammatory illness that causes joint destruction and dysfunction due to the activation of macrophages and the generation of reactive oxygen species. Current therapy choices frequently limit the effectiveness of targeting the inflammatory areas. To reduce inflammation and oxidative stress in RA, this research will create and assess multifunctional nanoparticles that selectively target inflammatory cells and deliver therapeutic medicines. Tannic acid, ferric chloride hexahydrate, methotrexate (MTX), and bovine serum albumin were conjugated using sonication and centrifugation to create the nanoparticles. Folic acid was added to improve the ability to target. Transmission electron microscopy, dynamic light scattering (DLS), UV-vis spectroscopy, and in vitro release experiments were used to characterize the nanoparticles. RAW 264.7 macrophage cells were used to test the cellular uptake of the nanoparticles using confocal microscopy and fluorescence-activated cell sorting (FACS). TFMBP-FA achieved 65.56%, and TFMBP reached 68.96%, indicating a high drug delivery rate for the synthesized nanoparticles. Confocal microscopy showed that the TFMBP-FA group had a greater density of fluorescent markers, indicating that the cells effectively targeted and absorbed the inflammatory environment. These results imply that the created nanoparticles may improve how medications are delivered during RA therapy.
Advancing sustainable agriculture: Metal-doped urea–hydroxyapatite hybrid nanofertilizer for agro-industry
Authors: Waheed Zohaib , Anwar Aneela , Sadiqa Ayesha , Ahmad Awais , Intisar Azeem , Javaid Arshad , Khan Iqra Haider , Khan Bushra Nisar , Khan Shahzeb , Kazi Mohsin 
Published: October 2024

Abstract
Nanotechnology holds excessive potential for addressing agricultural challenges such as soil deprivation, nutrient deficiencies, low harvests, and nutrient leaching. Nanofertilizers enable more efficient nutrient absorption by plants due to their enlarged surface area, bestowing viable solutions. Urea–hydroxyapatite hybrid (urea–HA hybrid) was successfully synthesized via a coprecipitation approach by doping nanohydroxyapatite with copper and zinc along with urea. The synthesized nanohybrids were analyzed by applying various techniques such as Fourier transform infrared spectroscopy, energy-dispersive spectroscopy (EDS), scanning electron microscopy, and X-ray powder diffraction (XRD). The evidence for the crystalline structure of HA was confirmed by peaks present in XRD analysis at 25.89°, 28.77°, and 32.11°, while urea was validated at 39.29°. The nanosized HA hexagonal nanorods were approximately 16 ± 1.5 nm, with the incorporation of urea, Cu, and Zn. The components of urea–HA hybrid (Ca, P, C, O, and N) were confirmed by EDS analysis with traces of Si. Antibacterial and antifungal activities were investigated against phytopathogenic microbes. The nanohybrid significantly inhibits the growth of Clavibacter michiganensis, Xanthomonas campestris, Macrophomina phaseolina, and Sclerotium rolfsii. A fertilization trial using urea–HA hybrid on Citrus limon has demonstrated a growth of 30 cm within 8 weeks of treatment, accompanied by brighter-colored leaves. Thus, the synthesized urea–HA hybrid enabled the slow release of nutrients, which had a significant impact on plant growth and will also effectively manage disease control against phytopathogens. Thus, this innovative approach addresses agricultural challenges regarding nutrient delivery and disease control more effectively.